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Abstract
Background: The xenobiotic enzyme system that enables us to detoxify carcinogens exhibits
identifiable genetic polymorphisms that are highly race specific. We hypothesized that
polymorphisms of these genes may be associated with risk of thyroid cancer. To evaluate the role
of genetic polymorphisms of xenobiotic genes in thyroid cancer, we conducted a hospital-based
case-control study in Saudi population.
Methods: 223 incident papillary thyroid cancer cases and 513 controls recruited from Saudi
Arabian population were analyzed for the association between polymorphisms in genes encoding
folic acid metabolizing enzymes MTHFR and six xenobiotics-metabolizing enzymes including
CYP1A1 T3801C, C4887A, GSTP1 A1578G, C2293T, GSTM1, GSTT1, NAT2 G590A, NQO*1 C609T,
using PCR-RELP.
Results:  Among selected genes, CYP1A1 C4887A genotypes CA, AA and variant allele A
demonstrated significant differences and greater risk of developing thyroid cancer comparing to
wild type genotype CC (CA vs. CC; p < 0.0001, OR = 1.91, 95% CI = 1.36–2.70, AA vs. CC; p <
0.001, OR = 3.48, 95% CI = 1.74–6.96 and CA+AA vs. CC; p < 0.0001, OR = 2.07, 95% CI = 1.49–
2.88). GSTT1 null showed 3.48 times higher risk of developing thyroid cancer (p < 0.0001, 95% CI
= 2.48–4.88) while GSTM1 null showed protective effect (p < 0.05, OR = 0.72, 95% CI = 0.52–0.99).
Remaining loci demonstrated no significance with risk.
Conclusion: Of the 9 polymorphisms screened, we identified GST, GSTM1 and CYP1A1 C4887A,
may be of importance to disease process and may be associated with papillary thyroid cancer risk
in Saudi Arabian population.
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Background
Thyroid cancer is the most common endocrine malig-
nancy, accounting for 3% of all cancers and is the eighth
most common malignancy in the United States [1]. In
contrast, in Kuwait, thyroid cancer ranks second, compris-
ing 8% of all female cancers [2] and similar findings have
been reported for other countries in the Gulf region [3].
Thyroid cancer is the fourth most common cancer and
overall accounting for 6.1% in Saudi Arabia representing
3.8% male and 10.8% female malignant neoplasms, sec-
ond to breast cancer [4]. Papillary thyroid carcinoma is
the predominant type, accounting for almost all (approx-
imately 90%) thyroid malignancies [5]. Although the
exact etiology of thyroid cancer remains unknown, expo-
sure to ionizing radiation is the only verified cause of thy-
roid carcinogenesis in humans, especially when exposure
occurs at young age, although dietary iodine deficiency
has also been linked to this pathology [6-8]. However,
individuals without previous exposure to ionizing radia-
tion can also develop thyroid cancers, usually defined as
sporadic tumors [9], suggesting that other risk factors
could also be involved in the etiology of sporadic tumors.
It has also been suggested that individuals possessing a
modified ability to metabolize carcinogens are at
increased risk of cancer [10-12]. For this reason, five (5)
families of genes encoding for enzymes controlling oxida-
tive stress have attracted our interest CYPs (Phase I Cyto-
chromes P450), GSTs (Phase II Glutathione-S-Transferase),
NADPH (quinone oxidoreductase NQO1), NAT (N-acetyl-
transferases), and gene encoding folic acid metabolizing
enzyme, Methylenetetrahydrofolate reductase (MTHFR).
MTHFR balances the pool of folate coenzymes in one car-
bon metabolism of DNA synthesis and methylation, both
are implicated in carcinogenesis of many types of cancer.
Previous reports concerning MTHFR gene polymorphisms
suggests that individuals carrying the less active form of
folate metabolizing enzyme will be at greater risk of can-
cer [10-12].
The N-acetyltransferases (NAT) are involved in the metab-
olism of drugs and environmental toxins. They catalyze
the acetyltransfer from acetylcoenzyme A to an aromatic
amine, heterocyclic amine or hydrazine compound.
Sequence variations in the human NAT1 and NAT2 result
in the production of NAT proteins with variable enzyme
activity or stability, leading to slow or rapid acetylation.
Therefore, genetic polymorphisms in NAT1  and  NAT2
have been associated with drug-induced toxicities and dis-
ease [13-15].
NQO1 is acytosolic enzyme catalyzing a 2 electron reduc-
tion of quinone and preventing their participation in
redox cycling and thus inoxidative stress [16]. Polymor-
phism within NQO1  has shown to be associated with
increased risk of myeloid leukemia [17], bladder carci-
noma [18].
CYP1A1 catalyzes the oxidation of polycyclin aromatic
hydrocarbons (PAHs) to epoxides and is inducible by PAH.
Although several case control studies have reported an
association between CYP1A1 polymorphism and suscep-
tibility to a number of adult cancers, others reported no
evidence of such association [19-22].
Glutathione S-transferases (GSTs) are a family of enzymes
that carry out a wide range of functions in cells. GSTs also
play a role in detoxification of a variety of endogenous
and exogenous electrophilic compounds, such as the
removal of reactive oxygen species and regeneration of S-
thiolated proteins that are products of oxidative stress and
the detoxification of carcinogenic compounds. In addi-
tion to this, GSTs modulate the induction of other
enzymes and proteins important for cellular functions,
such as DNA repair [23]. This class of enzymes is therefore
important for maintaining cellular genomic integrity and
as a result may play an important role in cancer suscepti-
bility. Several studies have shown that GSTM1 0/0 is asso-
ciated with an increased risk of lung, bladder, gastric,
colorectal, and laryngeal cancers [24-28], although not of
skin cancer development [29]. Thus carcinogenesis could
be related to the absence of the functional GSTM1 alleles.
In the thyroid, many studies related to genes such as p53,
RAS RET and thyrotropin receptor have improved our
understanding of thyroid carcinogenesis [30].
We investigated the association between polymorphisms
in genes encoding folic acid metabolizing enzymes
MTHFR and six xenobiotics-metabolizing enzymes
including  CYP1A1 T3801C, C4887A, GSTP1 A1578G,
GSTP1 C2293T, GSTM1, GSTT1, NAT2 G590A, NQO*1
C609T, since genetic differences in these genes are highly
race specific and have never been screened in the Saudi
PTC cases. We hypothesized that polymorphisms of genes
responsible for drug metabolism xenobiotic genes may be
associated with risk of thyroid cancer.
Methods
Study Subjects
Formalin fixed, paraffin embedded samples from 223
newly presenting and previously untreated Arabian
patients with papillary thyroid carcinoma (PTC) were
investigated. PTC patient samples (n = 223) were readily
available from the archives of the Pathology Department
at King Faisal Specialist Hospital and Research Centre
(KFSHRC). The Institutional Review Board of the King
Faisal Specialist Hospital and Research Centre approved
the study in accordance with the Declaration of Helsinki.
Diagnosis was confirmed by pathologic review using theBMC Medical Genetics 2008, 9:61 http://www.biomedcentral.com/1471-2350/9/61
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diagnostic criteria defined in the WHO Classification [31].
Briefly, tissue cylinders with a diameter of 0.6 mm were
punched from representative tumor regions of each
"donor" tissue block by using a home made semiauto-
matic robotic precision instrument as described [32].
Genomic DNA was extracted from paraffin embedded
PTC tissues using the Puregene DNA isolation kit (Gentra,
Minneapolis, MN) following the manufacturer's recom-
mendations. Genotypes frequency data of GSTM1,
GSTT1, CYP1A1 T3801C and C4887A, MTHFR C677T,
GSTP1 A1578G and C2293T, NQO*1 C609T and NAT2
G590A for control population utilized in this report was
from our previous study [33], briefly, whereby peripheral
blood was obtained from age matched, 513 individual
healthy blood donors of Middle Eastern Arab origin (95%
Saudi Arabians and 5% from other Arab countries such as
Jordan, Syria, Lebanon, Yemen) visiting the Blood Bank at
KFSHRC, Riyadh, Saudi Arabia.
Genotyping
We first determined that the use of Hotstart Taq polymer-
ase allowed us to apply the same PCR conditions to opti-
mally amplify each of the variant alleles for all genes
studied. PCR reactions were performed in 25 μl contain-
ing 50 ng of genomic DNA, 12.5 pmol each primer, 200
μM of each dNTPs, 2.5 mM MgCl2 and 0.5 units Hotstart
Taq DNA Polymerase. After denaturation for 10 minutes
at 95°C, each PCR was performed for 35 cycles of 1
minute at 95°C, 1 minute at 59°C and 1.5 minutes at
72°C. The final elongation step was 10 minutes. Negative
non-template controls were included in each PCR. The
same aliquot of DNA was used to analyze all SNPs. PCR
products were directly analyzed on a 2.5% agarose gel.
MTHFR Polymorphisms
MTHFR C677T was amplified using primers: (5-TGAAG-
GAGAAGGTGTCTGCGGGA-3 and 5-AGGACGGTGCG-
GTGAGAGTG-3), the MTHFR C677T genotypes CC
(wildtype) produced one 198-bp band, MTHFR  TT
(homozygote mutation) produced two bands of 175-bp
and 23-bp, while MTHFR C677T CT (heterozygote) sam-
ples exhibited a digestion pattern of all three bands when
digested with Hinf I.
CYP1A1 Polymorphisms
Using primers: (5-GGCTGAGCAATCTGACCCTA-3 and 5-
TAGGAGTCTTGTCTCATGCCT-3), the CYP1A1 T3801C
genotypes TT (wildtype) produced a 341-bp band,
CYP1A1 CC (homozygote mutation) produced two bands
of 175-bp and 166-bp, while CYP1A1 T3801C TC (heter-
ozygote) samples exhibited a digestion pattern of all three
bands when digested with MSP I. CYP1A1 C4887A gene
(rs1048943) was determined using primers (5-CTGTCTC-
CCTCTGGTTACAGGAAGC-3 and 5-TTCCACCCGTT-
GCAGCAGGATAGCC-3), and Bsa I was used to digest the
204-bp product: CYP1A1 C4887A CC (wildtype) pro-
duced two bands, a 138-bp and 66-bp, CYP1A1 C4887A
AA (homozygote mutation) produced one band of 204-
bp, while CYP1A1 C4887A CA (heterozygote) samples
exhibited a digestion pattern of all three bands (204-bp,
138-bp and 66-bp) when digested with Bsa I.
GSTP1 Polymorphisms
Using primers: (5-GGCTCTATGGGAAGGACCAGCAGG-
3 and 5-GCACCTCCATCCAGAAACTGGCG-3), the
GSTP1 A1578G (rs947894) genotype AA (wildtype) pro-
duced a 256-bp band, GSTP1 GG (homozygote mutation)
produced two bands of 204-bp and 52-bp, while GSTP1
A1578G AG (heterozygote) samples exhibited a digestion
pattern of all three bands when digested with BsmA I.
Similarly, using primers: (5-CAGCAGAGGCAGCGTGT-
GTGC-3 and 5-CCCACAATGAAGGTCTTGCCTCC-3), the
GSTP1 C2293T (rs1799811) CC (wildtype) produced two
bands, a 120-bp and 97-bp, GSTP1 C2293T TT (homozy-
gote mutation) produced one band of 217-bp, while
GSTP1 C2293T CT (heterozygote) samples exhibited a
digestion pattern of all three bands (217-bp, 120-bp and
97-bp) when digested with Aci I.
NQO*1 Polymorphisms
NQO*1 C609T was amplified using primers: (5-AGT-
GGCATTCTGCATTTCTGTG-3 and 5-GATGGACTT-
GCCCAAGTGATG-3), the NQO*1 C609T genotypes CC
(wildtype) produced two bands, a 188-bp and 85-bp
band, NQO*1 TT (homozygote mutation) produced three
bands of 151-bp, 85-bp and 37-bp, while NQO*1 C609T
CT (heterozygote) samples exhibited a digestion pattern
of all four bands when digested with Hinf I.
NAT2 Polymorphisms
NAT2 G590A was amplified using primers: (5-CCTGGAC-
CAAATCAGGAGAG-3 and 5-ACACAAGGGTTTATTTTGT-
TCC-3), the NAT2 G590A genotypes GG (wildtype)
produced three bands, a 170-bp, 139-bp and 112-bp
band, NAT2 AA (homozygote mutation) produced two
bands of 309-bp and 112-bp, while NAT2 G590A GA (het-
erozygote) samples exhibited a digestion pattern of all
four bands when digested with Taq I.
GSTM1 and GSTT1 Polymorphisms
The presence or absence of GSTM1 and GSTT1 was deter-
mined by multiplex PCR in which β-globin gene was co-
amplified as an internal control. GSTM1 was amplified
using primers 5-GAACTCCCTGAAAAGCTAAAGC-3 and
5-GTTGGGCTCAAATATACGGTGG-3. Wherever present
GSTM1 produced a 219-bp band along with 110-bp β-
globin  amplified with primers 5-ACACAACTGTGT-
TCACTAGC-3 and 5-CAACTTCATCCACGTTCACC-3.
Similarly, GSTT1 produced 480-bp band along with 110
β-globin band. GSTT1 was amplified using primers 5-TTC-BMC Medical Genetics 2008, 9:61 http://www.biomedcentral.com/1471-2350/9/61
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CTTACTGGTCCTCACATCTC-3 and 5-TCACCGGATCAT-
GGCCAGCA-3. Absence of 219-bp band for GSTM1 or
480-bp for GSTT1 with the presence of 110 β-globin was
recorded as deleted.
Statistical Analysis
Univariate analysis using Chi-square analyses (two-sided)
was first performed to compare the differences in geno-
type and allele frequencies between case and control sub-
jects. The odds ratio (OR) and 95% confidence interval
provide a measure for the strength of association, e.g.
indicating the increase in the odds of a given benign or
malignant thyroid tumor demonstrating a particular gen-
otype compared with the control population. Statistical
significance of the differences in the frequency of geno-
types was assessed, applying two-sided Fisher's exact test,
and odds ratios (ORs) with 95% CI were calculated on the
SPSS statistical package (version 11.0). All tests were con-
ducted at the p < 0.05 level of significance.
Table 1: Distribution of polymorphisms in healthy population and thyroid cancer patients (n = 50).
Polymorphism Genotype Control PTC p* OR$ 95% CI
MTHFR C667T CC 372(72.8%) 30(61.2%)
CT 126(24.7%) 18(46.15%) 0.09 1.77 0.96–3.29
TT 13(2.5%) 1(2.6%) 1 0.95 0.12–7.54
CT+TT 139(27.2%) 19(48.7%) 0.10 1.70 0.92–3.11
CYP1A1 T3801T TT 327(64.2%) 27(57.4%)
TC 157(30.9%) 15(31.9%) 0.73 1.16 0.60–2.24
CC 25(4.9%) 5(10.6%) 0.09 2.42 0.86–6.83
CC+TC 182(35.8%) 20(42.5%) 0.35 1..33 0.73–2.44
CYP1A1 C4887A CC 331(64.8%) 7(16.7%)
CA 162(31.7%) 30(71.4%) < 0.0001 8.76 3.77–20.36
AA 18(3.5%) 5(11.9%) < 0.0001 13.14 3.79–45.47
CA+AA 180(35.2%) 35(83.3%) < 0.0001 9.19 4.00–21.12
GSTP1 A1578G AA 170(33.5%) 18(38.3%)
AG 271(53.5%) 25(53.2%) 0.74 0.87 0.46–1.65
GG 66(13%) 4(8.5%) 0.45 0.57 0.19–1.75
AG+GG 337(66.5%) 29(61.7%) 0.52 0.81 0.44–1.51
GSTP1 C2293T CC 389(76.3%) 30(75%)
CT 113(22.2%) 8(20%) 1 0.92 0.41–2.06
TT 8(1.5%) 2(5%) 0.17 3.24 0.66–15.95
CT+TT 121(23.7%) 10(25%) 0.85 1.07 0.51–2.26
GSTM1 P 233(45.4%) 24(48%)
D 280(54.6%) 26(52%) 0.77 0.90 0.50–1.61
GSTT1 P 385(75%) 16(32.7%)
D 128(25%) 33(67.3%) < 0.0001 6.24 3.31–11.64
NAT2 G590A GG 284(55.4%) 19(46.3%)
GA 181(35.3%) 17(41.5%) 0.34 1.40 0.71–2.77
AA 47(9.2%) 5(12.2%) 0.37 1.59 0.57–4.47
GA+AA 228(44.5%) 22(53.7%) 3.29 1.44 0.76–2.73
NQO*1 C609T CC 295(58.5%) 30(61.2%)
CT 177(35.1%) 18(36.7%) 1 1 0.54–1.85
TT 32(6.4%) 1(2.04%) 0.34 0.31 0.04–2.33
CT+TT 209(41.5%) 19(38.74%) 0.76 0.89 0.49–1.63
* Statistical significance of the differences in the frequency of genotypes was assessed, applying two-sided Fisher's exact test to compare between 
case and control subjects.
$ The odds ratio (OR) providing a measure for the strength of association demonstrating a particular genotype compared with the control 
population calculated using the SPSS statistical package (version 11.0).
P = Present and D = Deletion for GSTM1 and GSTT1 geneBMC Medical Genetics 2008, 9:61 http://www.biomedcentral.com/1471-2350/9/61
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Results
Tables 1, 2 provide detailed information on the frequency
of the multiple genotypes analyzed. 223 PTC samples
were included in this study. Initially, only 50 out of 223
PTC samples were analyzed for 9 SNPs in 7 genes (Table
1). Furthermore, comparing cases with the control study
group the association between polymorphisms and the
risk to develop thyroid cancer was initially assessed with
50 PTC samples and the SNP's that showed statistical sig-
nificance were selected to further confirm the finding with
larger number of cases analyzed (n = 223) (Table 2).
Frequencies for CYP1A1 C4887A genotypes CC, CA, AA
and CA+AA were 16.7%, 71.4%, 11.9% and 83.3%
respectively and frequency of A allele was 48% when ini-
tial analysis with 50 cases was performed. Genotype CA
showed 8.7-fold, AA showed 13.1-fold and CA+AA dem-
onstrated 9.2-fold higher risk, compared with wild type (p
< 0.0001). On the other hand, analysis of CYP1A1
T3801C showed no statistical significance (Table 1).
Although GSTP1 C2293T, genotype TT accounted for 5%
of PTC cases comparing with 1.5% of controls and
showed 3.24 fold higher risk to develop thyroid cancer
but did not reached to level of significance (Table 1).
Among 50 PTC cases, 67.3% were homogenous for the
GSTT1  null genotype compared with 25% of controls.
Consequently there was 6.24 fold increase in the risk of
thyroid cancer associated with GSTT1 null genotype (OR
= 6.24). No significant differences were found in the fre-
quency of other genes when 50 cases were compared with
controls (Table 1).
Using our selection criteria, in particular two genes from
xenobiotic metabolizing enzyme system (CYP1A1
C4887A and GSTT1) were chosen to elaborate the study
with further 173 cases, since they have demonstrated high
statistical significance and odds ratio when controls were
compared to initially analyzed 50 cases form PTC sam-
ples. Additionally two genes, GSTM1 and NAT2 G590A,
which have shown no statistical significance, were also
selected for further analysis to confirm the reliability of
our selection criteria. 173 further PTC cases were analyzed
for these four genes and compared with control case
group to assess the association between polymorphisms
and the risk to develop thyroid cancer. Although the ini-
tial selection criteria was not deemed statistically powerful
due to less number of samples nevertheless provided with
the selection of genes to expand the study with statistically
significant data. As can be seen GSTM1 and NAT2 G590A
Table 2: Distribution of Xenobiotic genes polymorphisms in healthy population and PTC cases (n = 223).
Polymorphism Genotype Control group PTC Cases p* OR$ (95%CI)
CYP1A1 C4887A
CC 331 (64.8%) 95 (47%)
CA 162 (31.7%) 89 (44%) < 0.0001 1.91 (1.36–2.70)
AA 18 (3.5%) 18 (10%) < 0.001 3.48 (1.74–6.96)
CA+AA 180 (35.2%) 107 (53%) < 0.0001 2.07 (1.49–2.88)
NAT2 G590A
GG 284 (55.4%) 99 (50%)
GA 181 (35.3%) 81 (41%) 0.180 1.28 (0.91–1.82)
AA 47 (9.2%) 18 (9%) 0.76 1.11 (0.61–1.98)
GA+AA 228 (44.5%) 99 (50%) 0.21 1.25 (0.90–1.73)
GSTT1
P 385 (75%) 96 (46.37%)
D 128 (25%) 111 (53.62%) < 0.0001 3.48 (2.48–4.88)
GSTM1
P 233 (45.4%) 109 (53.7%)
D 280 (54.6%) 94 (46.3%) 0.047 0.72 (0.52–0.99)
GSTM1+GSTT1
P 423 (82.8) 159 (78.32%)
D 88 (17.2%) 48 (23.64%) 0.074 1.45 (0.98–2.16)
* Statistical significance of the differences in the frequency of genotypes was assessed, applying two-sided Fisher's exact test to compare between 
case and control subjects.
$ The odds ratio (OR) providing a measure for the strength of association demonstrating a particular genotype compared with the control 
population calculated using the SPSS statistical package (version 11.0).
P = Present and D = Deletion for GSTM1 and GSTT1 geneBMC Medical Genetics 2008, 9:61 http://www.biomedcentral.com/1471-2350/9/61
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genes, demonstrated no significant association with risk
estimate compared to control group even when expanded
with 173 more PTC samples (tables 1 and 2).
Among selected genes, frequencies for CYP1A1 C4887A
genotypes CC, CA, AA and CA+AA were 47%, 44%, 9%
and 53% respectively and frequency of A allele was 31%.
Genotypes CA, AA and variant allele A demonstrated sig-
nificant differences comparing to wild type genotype CC.
Odds ratio showed CA has 1.9 fold, while AA has 3.4 fold
and variant allele A showed 2 fold greater risk of develop-
ing thyroid cancer comparing to wild type.
GSTT1 null showed 3.48 times higher risk of developing
thyroid cancer (p < 0.0001) while GSTM1 null showed
protective effect (p < 0.05, OR = 0.718). Although the
GSTT1 null was risk factor (OR = 3.48) to develop PTC (p
< 0.0001) but double null of GSTT1 and GSTM1 showed
no statistical significance (Table 2).
We also investigated whether the prevalence of combined
GSTT1 null and GSTM1 null genotype (double-null geno-
type) was significantly increased in PTC cases compared
with controls (Table 2). Among PTC cases, 23.6% were
both GSTT1 and GSTM1 null, compared with 17.2% of
controls. When individuals with both GSTT1 and GSTM1
were considered as the reference group, analysis demon-
strated comparatively lower increased risk (OR = 1.45) in
individuals with the double-null genotype than that seen
with GSTT1 null alone, but the results did not reach the
level of significance.
Discussion
Multiple enzyme pathways are involved in detoxification
of chemotherapeutic agents and/or carcinogens. Varia-
tions in GSTT1, GSTM1 and GSTP1 have been previously
demonstrated to influence drug efficacy and toxicity and
also to modify individual susceptibility to cancers [34-39]
however, there are scarce data specific to patients with thy-
roid cancer [40-46]. Host factors may contribute to an
individual's risk of developing secondary cancers. Our
findings suggest that polymorphisms of certain xenobi-
otic metabolizing enzyme genes modify the individual
susceptibility to develop thyroid cancer in the Saudi pop-
ulation. Our findings from this hospital-based case-con-
trol study are not entirely consistent with previous
published studies.
GSTs participate in the metabolism of alkylating agents,
anthracyclines and steroids and variations in within these
genes can significantly influence treatment outcome
[35,36]. The different glutathione S-transferase (GST)
enzymes have classically been considered as an important
part of the cell defense against numerous harmful chemi-
cals and reactive oxygen species (ROS) produced endog-
enously and in the environment [48-52]. Their
importance is suggested by the finding that mutations in
GST genes have been associated with susceptibility to var-
ious diseases, in particular with cancer [48].
The only three studies published so far on involvement of
GSTT1 and GSTM1 null alleles in thyroid cancer risk were
carried out in three different regions with different fre-
quencies of GST deletion genotype in general population
(Spain, Brazil and Portugal) [45,52,53]. Contrary to our
findings the results obtained in three recently published
studies [45,52,53] did not show increased risk between
the GST polymorphisms and papillary and follicular thy-
roid cancer susceptibility. We found that the GSTT1 null
genotype was associated with high risk (OR = 3.478, p <
0.0001) of developing PTC. Although our findings,
showed association between the GSTM1  null genotype
with decreased risk against development of PTC (OR =
0.718, p < 0.05) comparing to control group, is consistent
with previous reports with other cancers [19,20,52,53]
including thyroid cancer [43]. Contrary to our findings
Canbay et al., in a short study with 32 thyroid samples and
44 controls demonstrated association of GSTM1 null gen-
otype with high risk of developing thyroid cancer in
patients stratified with age [46]. Other thyroid cancer
studies showed that only the combination of GSTM1 and
GSTT1 null inheritance [53] or only the presence of three
potentially risk alleles, namely GSTM1-null, GSTT1-null
and GSTP1 A1578G genotype GG [46], leads to significant
increase in adjusted odds ratio for papillary and follicular
thyroid cancers. These results were not confirmed by the
third study conducted on a Spanish population [52]. Our
data showed weak association with double null genotypes
GSTT1+GSTM1, and risk of PTC (OR = 1.451, p = 0.074)
(Table 2). Although with limited number of cases (n = 50)
we did not find any statistical association with GSTP1
A1578G genotypes but nonetheless our findings in PTC
for GSTP1 C2293T with genotypes TT showed non-signif-
icant association with elevated risk of PTC (OR = 3.242).
The GSTT1 and GSTM1 null allele frequency among con-
trols in the Brazilian, Spanish and other European studies
[52] demonstrated marked variation compared to ours
(17.2% vs. 5, 10.3 and 9.2%). Thus, the differences in our
finding with published data could indicate role of these
genotypes distinct to Saudi population. Morari et al. [53]
consistent with our data showed that papillary carcinoma
patients (17%) and follicular carcinoma patients (10%)
presented a higher prevalence of the combined GSTT1/M1
null genotype than the normal population individuals
(5%; OR 2.6; 95% CI, 1.044–6.355; p < 0.05). Similar to
others [52,53] our results demonstrated higher frequency
of combined GSTT1/M1  null genotype in PTC than in
control group 23.6% vs. 17.2%). In addition, the fre-BMC Medical Genetics 2008, 9:61 http://www.biomedcentral.com/1471-2350/9/61
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quency of null GSTT1 in our patients was two fold higher
than in control group (53.6% vs. 25%).
In the present study, an increased risk of developing PTC
associated with the GSTT1 null and protective effect of
GSTM1 null allele was suggested, although not reaching
the statistical significance but demonstrated trend
towards increased risk with double, GSTT1 and GSTM1
null genotype.
CYP1A1  genes are associated with higher enzymatic
inducibility. Levels of circulating hormone are affected by
genetic variability, and analysis of genetic polymorphisms
that influence estrogen production may provide insight
into its potential role in carcinogenesis. Estrogen exerts
pleotropic effects on lymphocyte activation, proliferation,
cell cycle progression and apoptosis [56], factors that may
influence thyroid cancer risk. Additionally depending on
levels, cortisol can either suppress or stimulate immune
function, so modulation of its production could poten-
tially influence thyroid cancer risk. In our study, CYP1A1,
phenotype AA demonstrated strong association with
increased risk of developing PTC (OR = 3.484, p < 0.001).
Additionally other CYP1A1 C4887A genotypes CA (OR =
1.914, p < 0.0001) and variant allele A (OR = 2.071, p <
0.0001) also demonstrated two fold high risk of develop-
ing PTC compared to the wild type. Recently we also dem-
onstrated significantly high differential expression of
CYP1A1 gene in PTC compared to normal counterparts,
support the notion and may suggest a possible role for
estrogen and possibly other cholesterol metabolites
formed via CYP1A1 C4887A in the pathogenesis of PTC
[57]. Scarce data is available on the association between
CYP1A1  polymorphism and increased susceptibility to
thyroid cancer. Recently Bufalo et al., in an extensive study
investigating CYP1A1 (m1 and m2) role in thyroid tumor-
igenesis and its connection with GSTM1, GSTT1, GSTP1,
GSTO1, and codon 72 of p53 genotypes, demonstrated an
inverse association between germline CYP1A1 inheritance
and smoking with the risk of thyroid nodules and papil-
lary carcinomas [58].
The reasons for these divergent results are not clear but are
likely racial differences because the frequencies of
CYP1A1, GSTT1, GSTM1, GSTP1 and NQO1 in our con-
trols were different from those found in other studies [33].
For instance certain SNPs like CYP1A1  A4889G and
GSTP1 A1578G were not in Hardy-Weinberg equilibrium
in the control samples which is contradicting comparing
to other population based data. In order to question the
specificity of the assay and to rule out the possibility of
uncompleted digestion due to inactivation of enzymes or
inhibitors in digestion mixture, we repeated the assays
multiple and over period of time. Consistent results were
obtained demonstrating this to be the true feature in our
population.
Consideration must also be given to potential limitation
of the present study and that is the nature of the control
subjects enrolled which weakens the study to be claimed
purely case: control. Although controls were matched
with respect to age but there was gender differences, with
preponderance of male blood donors (25:1). While this
initial documentation of allelic frequencies in the Arabs
may be biased because of the nature of subjects enrolled
(preponderance of male blood donors), previous reports
have indicated only minimal influence of age and gender
on the distribution of these polymorphisms in a given
population.
Additionally, in our study PTC patient samples from par-
affin embedded tissues were readily available from the
archives of the Pathology Department at King Faisal Spe-
cialist Hospital and Research Centre (KFSHRC). Similarly
control group was randomly selected from DNA available
from peripheral blood samples at institutional Tissue
Biorepository Bank at KFSHRC. It would have been ideal
to analyze samples from uniform source (tissue only or
peripheral blood of patients and controls) but it was not
possible in our case since archival samples were used.
Since genetic aberrations, that could be present in the
tumor but possibly not in the "normal tissue" could con-
found analyses but to the best of our knowledge there are
no such reports suggesting somatic mutations in studied
genes in thyroid cases.
Obviously, further study with a larger sample size is
needed to confirm these findings and to examine the
interaction between genotypes. However, this study does
provide preliminary case-control data on several poly-
morphisms in genes of the xenobiotic pathways and risk
to develop thyroid cancer.
Conclusion
We hypothesized that polymorphisms of genes responsi-
ble for drug metabolism xenobiotic genes may be associ-
ated with risk of thyroid cancer. Of the 9 polymorphisms
screened, we identified GST, GSTM1 and CYP1A1 C4887A
may be of importance to this disease process. Obviously,
confirmatory studies with larger sample sizes will be
needed for other genes that showed no significance with
risk, but these findings represent a step toward the under-
standing of genetic susceptibility to thyroid cancer. If
these findings are confirmed, then genotypes could be
incorporated into future genetic profiles of thyroid cancer
risk and may serve in future cancer prevention efforts or
public health responses to accompanying risk factors.BMC Medical Genetics 2008, 9:61 http://www.biomedcentral.com/1471-2350/9/61
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